Calumet Specialty Products (CLMT) reported an unprecedented rapid turnaround in its business momentum within a single quarter, shifting from mediocre performance to strong growth prospects. This swift change is notable for its speed and scale, suggesting potential for sustained momentum and a possible re-rating of the stock. Long-term, the company could generate around $200 million in quarterly EBITDA excluding windfall profits. Investors are advised to watch CLMT closely for continued growth signals.
The global Bioprocess Automation Software market, valued at $1.67 billion in 2025, is projected to grow to $6.19 billion by 2035 at a 14% CAGR. This growth is fueled by the increasing demand for personalized medicine, flexible manufacturing processes...
The global microneedle drug delivery systems market is projected to grow from $7.04 billion in 2025 to $14.37 billion by 2035, at a CAGR of 7.4%. Growth is fueled by rising demand for minimally invasive, pain-free, and self-administered drug delivery...
Silvercorp Metals, a Canadian producer of silver, zinc, and gold, benefits from rising silver prices and strong industrial demand. The company maintains operational efficiency with a low all-in sustaining cost of $12.86 per ounce, supporting strong f...
RADCOM has entered a new phase with activist-driven board changes and a strong $108 million cash balance. Its recurring, high-margin revenue is anchored by a renewed multi-year contract with AT&T, reducing near-term revenue risks despite DISH's netwo...
Meltem Demirors argues that the rise of spot Bitcoin ETFs has caused a crisis in cryptocurrency's identity, shifting it from a decentralized alternative to a tool absorbed by traditional finance. While ETFs have increased institutional access, they h...
